002294 信立泰
已收盘 02-06 15:00:00
资讯
新帖
简况
信立泰（002294）披露控股股东部分股份解除质押公告，2月4日股价上涨4.27%
证券之星 · 02-04 22:10
信立泰（002294）披露控股股东部分股份解除质押公告，2月4日股价上涨4.27%
信立泰公布国际专利申请：“一种取代的血管紧张肽和内皮肽受体拮抗剂及其应用”
证券之星 · 01-31
信立泰公布国际专利申请：“一种取代的血管紧张肽和内皮肽受体拮抗剂及其应用”
信立泰公布国际专利申请：“PCSK9和HMG-CoA双靶化合物与应用”
证券之星 · 01-31
信立泰公布国际专利申请：“PCSK9和HMG-CoA双靶化合物与应用”
信立泰计划寻求香港上市
投资观察 · 01-21
信立泰计划寻求香港上市
信立泰最新公告：拟发行H股股票并在香港联交所主板上市
证券之星 · 01-21
信立泰最新公告：拟发行H股股票并在香港联交所主板上市
信立泰最新公告：董事沈清因个人原因辞职职工代表许文杰接任
证券之星 · 01-18
信立泰最新公告：董事沈清因个人原因辞职职工代表许文杰接任
信立泰(002294.SZ)：SAL0150片临床试验申请获受理
智通财经 · 01-09
信立泰(002294.SZ)：SAL0150片临床试验申请获受理
信立泰(002294.SZ)：SAL0145药品临床试验申请获受理
智通财经 · 01-07
信立泰(002294.SZ)：SAL0145药品临床试验申请获受理
异动快报：信立泰（002294）12月29日14点29分触及跌停板
证券之星 · 2025-12-29
异动快报：信立泰（002294）12月29日14点29分触及跌停板
信立泰（002294）披露关于SAL0137获得临床试验批准通知书，12月19日股价上涨1.55%
证券之星 · 2025-12-19
信立泰（002294）披露关于SAL0137获得临床试验批准通知书，12月19日股价上涨1.55%
信立泰(002294.SZ)：SAL0137获临床试验批准
智通财经 · 2025-12-19
信立泰(002294.SZ)：SAL0137获临床试验批准
信立泰最新公告：筹划发行H股股票并在香港联合交易所有限公司上市
证券之星 · 2025-12-11
信立泰最新公告：筹划发行H股股票并在香港联合交易所有限公司上市
信立泰（002294）披露召开2025年第一次临时股东大会通知，12月10日股价下跌3.31%
证券之星 · 2025-12-10
信立泰（002294）披露召开2025年第一次临时股东大会通知，12月10日股价下跌3.31%
信立泰(002294.SZ)：信超妥、复立安、恩那罗等药品纳入国家医保目录
智通财经 · 2025-12-08
信立泰(002294.SZ)：信超妥、复立安、恩那罗等药品纳入国家医保目录
信立泰最新公告：SAL0140片获得临床试验批准通知书
证券之星 · 2025-12-03
信立泰最新公告：SAL0140片获得临床试验批准通知书
11月26日信立泰涨5.69%，中欧医疗健康混合A基金重仓该股
证券之星 · 2025-11-26
11月26日信立泰涨5.69%，中欧医疗健康混合A基金重仓该股
信立泰（002294）披露SAL0139获得临床试验批准通知书，11月21日股价下跌1.59%
证券之星 · 2025-11-21
信立泰（002294）披露SAL0139获得临床试验批准通知书，11月21日股价下跌1.59%
信立泰(002294.SZ)：创新小分子药物SAL0139获批开展治疗高脂血症临床试验
智通财经 · 2025-11-21
信立泰(002294.SZ)：创新小分子药物SAL0139获批开展治疗高脂血症临床试验
信立泰（002294）披露将参加深圳辖区上市公司投资者网上集体接待日活动，11月14日股价下跌0.45%
证券之星 · 2025-11-14
信立泰（002294）披露将参加深圳辖区上市公司投资者网上集体接待日活动，11月14日股价下跌0.45%
11月13日信立泰涨5.40%，中欧医疗健康混合A基金重仓该股
证券之星 · 2025-11-13
11月13日信立泰涨5.40%，中欧医疗健康混合A基金重仓该股
加载更多
公司概况
公司名称：
深圳信立泰药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-09-10
主营业务：
深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物。
发行价格：
41.98
{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":47.32,"timestamp":1770361434000,"preClose":47.7,"halted":0,"volume":6878850,"delay":0,"changeRate":-0.008,"floatShares":1115000000,"shares":1115000000,"eps":0.6033,"marketStatus":"已收盘","change":-0.38,"latestTime":"02-06 15:00:00","open":47.52,"high":48.3,"low":46.46,"amount":328000000,"amplitude":0.0386,"askPrice":47.4,"askSize":14,"bidPrice":47.32,"bidSize":43,"shortable":0,"etf":0,"ttmEps":0.6033,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":47.7,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":52.47,"lowLimit":42.93,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"isCdr":false,"pbRate":6.06,"roa":"--","peRate":78.435273,"roe":"6.67%","epsLYR":0.54,"committee":-0.044248,"marketValue":52753000000,"turnoverRate":0.0062,"status":1,"floatMarketCap":52741000000},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2608360571","title":"信立泰（002294）披露控股股东部分股份解除质押公告，2月4日股价上涨4.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360571","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608360571?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:10","pubTimestamp":1770214233,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘，信立泰报收于48.15元，较前一交易日上涨4.27%，最新总市值为536.78亿元。近日，深圳信立泰药业股份有限公司发布公告，公司控股股东信立泰药业有限公司将其所持公司4,300万股股份解除质押，占其所持股份比例6.77%，占公司总股本比例3.86%。本次解除质押后，香港信立泰累计被质押股份数量为5,400万股，占其持股总数8.50%，占公司总股本4.84%。公司明确该股份质押不涉及业绩补偿义务，不影响公司实际控制权及生产经营。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0183","BK0028","BK0196","BK0239","002294","BK0188"],"gpt_icon":0},{"id":"2607022701","title":"信立泰公布国际专利申请：“一种取代的血管紧张肽和内皮肽受体拮抗剂及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2607022701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607022701?lang=zh_cn&edition=full","pubTime":"2026-01-31 06:45","pubTimestamp":1769813142,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示信立泰（002294）公布了一项国际专利申请，专利名为“一种取代的血管紧张肽和内皮肽受体拮抗剂及其应用”，专利申请号为PCT/CN2025/110261，国际公布日为2026年1月29日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来信立泰已公布的国际专利申请3个，较去年同期增加了50%。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.35亿元，同比增16.31%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013100005160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0188","BK0196","002294","BK0239","BK0187","BK0028"],"gpt_icon":0},{"id":"2607748022","title":"信立泰公布国际专利申请：“PCSK9和HMG-CoA双靶化合物与应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2607748022","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607748022?lang=zh_cn&edition=full","pubTime":"2026-01-31 06:45","pubTimestamp":1769813134,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示信立泰（002294）公布了一项国际专利申请，专利名为“PCSK9和HMG-CoA双靶化合物与应用”，专利申请号为PCT/CN2025/109569，国际公布日为2026年1月29日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来信立泰已公布的国际专利申请3个，较去年同期增加了50%。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.35亿元，同比增16.31%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013100005098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0196","BK0187","BK0188","BK0183","002294"],"gpt_icon":0},{"id":"1127825301","title":"信立泰计划寻求香港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1127825301","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127825301?lang=zh_cn&edition=full","pubTime":"2026-01-21 20:18","pubTimestamp":1768997938,"startTime":"0","endTime":"0","summary":"深圳信立泰药业股份有限公司（002294.SZ）宣布，公司计划寻求在香港交易所上市。这一举措标志着该制药企业可能迈入国际资本市场的新阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0183","BK0028","BK0196","BK0187","002294","BK0188"],"gpt_icon":0},{"id":"2605958101","title":"信立泰最新公告：拟发行H股股票并在香港联交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2605958101","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605958101?lang=zh_cn&edition=full","pubTime":"2026-01-21 20:01","pubTimestamp":1768996877,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，为进一步推进公司全球化战略布局，打造国际化资本运作平台，助力公司高质量发展，公司拟发行境外股份（H股）股票并申请在香港联合交易所有限公司主板挂牌上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100036532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0188","BK0183","BK0187","BK0239","BK0028","BK0196"],"gpt_icon":0},{"id":"2604729978","title":"信立泰最新公告：董事沈清因个人原因辞职职工代表许文杰接任","url":"https://stock-news.laohu8.com/highlight/detail?id=2604729978","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604729978?lang=zh_cn&edition=full","pubTime":"2026-01-18 18:30","pubTimestamp":1768732242,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，公司董事沈清因个人原因辞去董事职务，其原定任期至公司第六届董事会届满之日止。沈清辞职未导致公司董事会低于法定最低人数，其辞职报告自送达董事会时生效。同时，公司召开职工代表大会选举许文杰为公司第六届董事会职工代表董事，任期与第六届董事会一致。许文杰具有16年药物开发经验，是公司自主研发的信超妥核心专利的主要发明人。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800008529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002294","BK0183","BK0028","BK0196","BK0187","BK0239"],"gpt_icon":0},{"id":"2602320603","title":"信立泰(002294.SZ)：SAL0150片临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2602320603","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602320603?lang=zh_cn&edition=full","pubTime":"2026-01-09 19:36","pubTimestamp":1767958574,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司收到国家药品监督管理局核准签发的受理通知书，公司自主研发的创新药SAL0150片(项目代码：SAL0150)临床试验申请获得受理。公司本次提交的申请为SAL0150用于2型糖尿病及其并发症、肥胖或超重的临床试验申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0188","BK0196","002294","BK0239","BK0187","BK0028"],"gpt_icon":0},{"id":"2601874665","title":"信立泰(002294.SZ)：SAL0145药品临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601874665","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601874665?lang=zh_cn&edition=full","pubTime":"2026-01-07 18:42","pubTimestamp":1767782570,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司收到国家药品监督管理局核准签发的受理通知书，公司自主研发的创新药SAL0145注射液(项目代码：SAL0145)临床试验申请获得受理。公告显示，SAL0145是公司研发的具有自主知识产权的siRNA药物，公司本次提交的申请为SAL0145用于治疗MASH的临床试验申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0028","BK0239","002294","BK0187","BK0188","BK0183"],"gpt_icon":0},{"id":"2595204076","title":"异动快报：信立泰（002294）12月29日14点29分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2595204076","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595204076?lang=zh_cn&edition=full","pubTime":"2025-12-29 14:30","pubTimestamp":1766989845,"startTime":"0","endTime":"0","summary":"证券之星12月29日盘中消息，14点29分信立泰（002294）触及跌停板。其所属行业化学制药目前下跌。领涨股为多瑞医药。该股为医疗器械，减肥药，化学原料药概念热股。12月26日的资金流向数据方面，主力资金净流出691.36万元，占总成交额4.23%，游资资金净流入1538.3万元，占总成交额9.4%，散户资金净流出846.94万元，占总成交额5.18%。近5日资金流向一览见下表：信立泰主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900013823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0183","BK0187","BK0028","002294","BK0188"],"gpt_icon":0},{"id":"2592985001","title":"信立泰（002294）披露关于SAL0137获得临床试验批准通知书，12月19日股价上涨1.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592985001","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592985001?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:33","pubTimestamp":1766154793,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘，信立泰报收于56.38元，较前一交易日上涨1.55%，最新总市值为628.53亿元。该股当日开盘55.52元，最高57.44元，最低55.31元，成交额达2.07亿元，换手率为0.33%。近日，深圳信立泰药业股份有限公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0137片开展治疗脂蛋白增高的临床试验。脂蛋白水平升高是心血管疾病的独立危险因素。公司将按相关规定开展临床试验，后续进展将及时披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039596.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0183","002294","BK0187","BK0188","BK0028","BK0196"],"gpt_icon":0},{"id":"2592150586","title":"信立泰(002294.SZ)：SAL0137获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592150586","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592150586?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:33","pubTimestamp":1766136831,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0137片(项目代码：SAL0137)开展治疗脂蛋白(a)增高的临床试验。脂蛋白(a)[lipoprotein(a),Lp(a)]水平升高是冠心病、缺血性脑卒中、外周血管疾病、冠状动脉钙化及钙化性主动脉瓣狭窄等的独立危险因素。Lp(a)通过促动脉粥样硬化、促炎和促血栓形成等多种机制，增加心血管疾病(Cardiovascular disease,CVD)风险。临床前研究显示，SAL0137具有治疗Lp(a)增高的潜力，具有一定开发潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信立泰(002294.SZ)：SAL0137获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0183","BK0196","002294","BK0028","BK0188","BK0239"],"gpt_icon":0},{"id":"2590978735","title":"信立泰最新公告：筹划发行H股股票并在香港联合交易所有限公司上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2590978735","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590978735?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:51","pubTimestamp":1765450272,"startTime":"0","endTime":"0","summary":"信立泰公告称，公司正在筹划发行境外股份（H股）并在香港联合交易所有限公司上市事宜。目前，公司正与相关中介机构就本次发行上市的具体推进工作进行商讨，相关细节尚未确定。本次发行上市不会导致公司控股股东和实际控制人发生变化。本次发行上市能否通过审议、备案和审核程序并最终实施具有较大不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100031698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0187","BK0196","BK0028","BK0183","002294","BK0239"],"gpt_icon":0},{"id":"2590835975","title":"信立泰（002294）披露召开2025年第一次临时股东大会通知，12月10日股价下跌3.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590835975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590835975?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:49","pubTimestamp":1765360147,"startTime":"0","endTime":"0","summary":"截至2025年12月10日收盘，信立泰报收于59.08元，较前一交易日下跌3.31%，最新总市值为658.63亿元。该股当日开盘61.12元，最高61.3元，最低58.75元，成交额达2.56亿元，换手率为0.39%。公司近日发布公告称，深圳信立泰药业股份有限公司将于2025年12月25日召开2025年第一次临时股东大会，会议由第六届董事会召集。股权登记日为2025年12月18日。上述议案需经出席股东大会的股东所持表决权的2/3以上通过。中小投资者的投票情况将单独统计披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000028725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0188","BK0196","002294","BK0239","BK0187","BK0028"],"gpt_icon":0},{"id":"2589335450","title":"信立泰(002294.SZ)：信超妥、复立安、恩那罗等药品纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589335450","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589335450?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:11","pubTimestamp":1765185078,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，据国家医保局、人力资源社会保障部发布的《关于印发〈国家基本医疗保险、生育保险和工伤保险药品目录〉以及〈商业健康保险创新药品目录〉(2025年)的通知》，公司的药品信超妥(沙库巴曲阿利沙坦钙片)、复立安®(阿利沙坦酯吲达帕胺缓释片)，通过谈判新纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》乙类范围，恩那罗®(恩那度司他片)续约成功保留在医保目录内;信立坦(阿利沙坦酯片)调整至医保常规目录管理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信立泰(002294.SZ)：信超妥、复立安、恩那罗等药品纳入国家医保目录","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002294","BK0188","BK0196","BK0239","BK0187","BK0028","BK0183"],"gpt_icon":0},{"id":"2588175560","title":"信立泰最新公告：SAL0140片获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2588175560","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588175560?lang=zh_cn&edition=full","pubTime":"2025-12-03 18:10","pubTimestamp":1764756623,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)公告称，公司近日收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0140片开展治疗慢性肾脏病（CKD）的临床试验。SAL0140是公司具有自主知识产权的醛固酮合酶抑制剂，若能研发成功并获批上市，将有望为更多细分领域的患者提供新的用药选择，满足未被满足的临床需求。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300028857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0183","BK0188","BK0196","BK0187","002294","BK0239"],"gpt_icon":0},{"id":"2586723913","title":"11月26日信立泰涨5.69%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2586723913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586723913?lang=zh_cn&edition=full","pubTime":"2025-11-26 15:35","pubTimestamp":1764142524,"startTime":"0","endTime":"0","summary":"证券之星消息，11月26日信立泰涨5.69%，收盘报62.46元，换手率0.72%，成交量8.0万手，成交额4.96亿元。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共80家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。葛兰在任的基金产品包括:中欧明睿新起点混合，管理时间为2018年7月12日至今，期间收益率为63.69%；中欧医疗创新股票A，管理时间为2019年2月28日至今，期间收益率为56.94%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600017691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","BK0239","159760","BK0187","BK0183","BK0188","002294"],"gpt_icon":0},{"id":"2585149907","title":"信立泰（002294）披露SAL0139获得临床试验批准通知书，11月21日股价下跌1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149907","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585149907?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:30","pubTimestamp":1763735446,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，信立泰报收于60.1元，较前一交易日下跌1.59%，最新总市值为670亿元。公司近日发布公告称，深圳信立泰药业股份有限公司近日收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0139片开展治疗高脂血症的临床试验。若研发成功并获批上市，将有望为高脂血症患者提供新的用药选择，满足未被满足的临床需求，并丰富公司慢病领域的产品管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0028","BK0196","BK0188","BK0239","BK0187","002294"],"gpt_icon":0},{"id":"2585190253","title":"信立泰(002294.SZ)：创新小分子药物SAL0139获批开展治疗高脂血症临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2585190253","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585190253?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:03","pubTimestamp":1763712187,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0139片(项目代码：SAL0139)开展治疗高脂血症的临床试验。高脂血症是一种隐匿性强、危害广泛的代谢性疾病，长期未控制可引发多系统并发症，低密度脂蛋白胆固醇(LDL-C)相关的高胆固醇积累是导致心脑血管疾病的关键风险因素。临床前研究显示，SAL0139具有降低LDL-C的潜力，若能研发成功并获批上市，将有望为更多患者提供新的用药选择，提高患者依从性，满足未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"信立泰(002294.SZ)：创新小分子药物SAL0139获批开展治疗高脂血症临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0183","BK0028","BK0196","BK0187","002294","BK0188"],"gpt_icon":0},{"id":"2583502716","title":"信立泰（002294）披露将参加深圳辖区上市公司投资者网上集体接待日活动，11月14日股价下跌0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502716","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583502716?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:48","pubTimestamp":1763131699,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，信立泰报收于61.98元，较前一交易日下跌0.45%，最新总市值为690.96亿元。该股当日开盘61.99元，最高63.5元，最低61.05元，成交额达3.76亿元，换手率为0.54%。公司近日发布公告称，深圳信立泰药业股份有限公司将参加2025年度深圳辖区上市公司投资者网上集体接待日活动。公司管理层将就公司业绩、治理、发展战略、经营状况及可持续发展等问题与投资者在线交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400042132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0187","BK0188","BK0239","002294","BK0028","BK0196"],"gpt_icon":0},{"id":"2583552388","title":"11月13日信立泰涨5.40%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583552388","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583552388?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:31","pubTimestamp":1763022717,"startTime":"0","endTime":"0","summary":"证券之星消息，11月13日信立泰涨5.40%，收盘报62.26元，换手率0.68%，成交量7.58万手，成交额4.68亿元。重仓信立泰的前十大公募基金请见下表：该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为45.91。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共80家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300027706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","BK0187","BK0196","BK0239","159760","BK0028","002294"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770370540945,"stockEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":-0.0553},{"period":"3month","weight":-0.1834},{"period":"6month","weight":-0.0019},{"period":"1year","weight":0.6269},{"period":"ytd","weight":-0.0373}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":-0.0019},{"period":"3month","weight":0.0196},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.2621},{"period":"ytd","weight":0.027}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25188人(较上一季度增加4.87%)","perCapita":"44249股","listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","registeredCapital":"111481万元","survey":" 深圳信立泰药业股份有限公司的主营业务是药品、医疗器械产品的研发、生产、销售，以及专利授权许可。公司的主要产品是心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物。","listedPrice":41.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}